All In Biotech

Drug Trial Radar · NCT06164873

A Study of IBI362 9 mg in Chinese Adults With Obesity

A Randomized, Double-blind, Placebo-controlled Phase 3 Study Evaluating the Efficacy and Safety of IBI362 9 mg in Chinese Participants With Obesity (GLORY-2)

Last checked: Nov 19, 2026Latest source record: Aug 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 462 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

462

Actual

Start

Dec 27, 2023

Primary completion

Jun 27, 2025

Study completion Sep 19, 2025

Sponsor

Sponsor type
Industry
First posted
Dec 11, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical study evaluating the efficacy and safety of IBI362 9 mg in obese subjects. Subjects will be randomly assigned to IBI362 9 mg and placebo groups. All study treatment will be administered once-weekly and subcutaneously. The entire trial cycle includes a 2-week screening period, a 60-week double-blind treatment period, and a 12-week drug withdrawal follow-up period after the end of treatment.

Conditions

  • Obesity

Interventions

  • IBI362Drug

    Once-weekly injections of gradually increased doses of IBI362

  • PlaceboDrug

    Once-weekly injections of volume-matched placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change from Baseline in Body WeightTime frame: Week 60
  2. Proportion of Participants who Achieve ≥5% Body Weight ReductionTime frame: Week 60

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.